With strong three-month performance and significant growth potential, Compass Therapeutics, Inc. (NASDAQ:CMPX) secures a spot on our list of 12 Penny Stocks to Invest in Right Now.
A doctor in a lab coat holding a healthcare solution in his hands.
On November 10, 2025, Joseph Pantginis of HC Wainwright reiterated a “Buy” rating on Compass Therapeutics, Inc. (NASDAQ:CMPX) with a $24 price target. The advancement of the company’s pipeline, marked by the preclinical progress of CTX-10726, earned the trust of the analyst, who was particularly impressed with the substantial potential of the bispecific antibody. At SITC 2025, the drug demonstrated high-affinity target engagement and robust antitumor activity. The analyst also cited the molecule’s competitive advantage over agents such as ivonescimab and bevacizumab, reinforcing optimism as the phase 1 trial scheduled for 2026 approaches.
Meanwhile, Compass Therapeutics, Inc. (NASDAQ:CMPX) reported third-quarter 2025 results on November 5. The cash balance reached $220 million at the end of the third quarter, which will support operations through 2028. General and administrative expenses saw a substantial increase, rising from $8.6 million in the third quarter of 2024 to $12.8 million. Management also reiterated its expectations to deliver overall survival (OS) and progression-free survival (PFS) data for tovecimig by the end of the first quarter of 2026. This could support the company’s first BLA filing in the second half of 2026. At the same time, Compass reported encouraging results in the Phase 1 study of CTX-8371. The company posted a net loss of $14.3 million, or $0.08 per share, during the quarter.
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology company, develops antibody-based therapies targeting angiogenesis, immune activation and tumor evasion pathways.
While we recognize CMPX’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.
Disclosure: None.